These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
487 related articles for article (PubMed ID: 33027050)
1. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation. Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050 [TBL] [Abstract][Full Text] [Related]
2. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Huang M; Yan C; Xiao J; Wang T; Ling R Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059 [TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711 [TBL] [Abstract][Full Text] [Related]
4. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120 [TBL] [Abstract][Full Text] [Related]
5. The Genetic Duet of Liu J; Liu R; Shen X; Zhu G; Li B; Xing M J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570 [No Abstract] [Full Text] [Related]
6. [ Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125 [TBL] [Abstract][Full Text] [Related]
7. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012 [TBL] [Abstract][Full Text] [Related]
8. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population. Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112 [TBL] [Abstract][Full Text] [Related]
10. Effects of Coexistent BRAF Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854 [TBL] [Abstract][Full Text] [Related]
11. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. Sun J; Zhang J; Lu J; Gao J; Ren X; Teng L; Duan H; Lin Y; Li X; Zhang B; Liang Z PLoS One; 2016; 11(4):e0153319. PubMed ID: 27064992 [TBL] [Abstract][Full Text] [Related]
12. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032 [TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. Li C; Lee KC; Schneider EB; Zeiger MA J Clin Endocrinol Metab; 2012 Dec; 97(12):4559-70. PubMed ID: 23055546 [TBL] [Abstract][Full Text] [Related]
14. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas. Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110 [TBL] [Abstract][Full Text] [Related]
15. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3470-3481. PubMed ID: 35501518 [TBL] [Abstract][Full Text] [Related]
16. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222 [TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma. Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713 [TBL] [Abstract][Full Text] [Related]
19. Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. Pessôa-Pereira D; Medeiros MFDS; Lima VMS; Silva JCD; Cerqueira TLO; Silva ICD; Fonseca LE; Sampaio LJL; Lima CRA; Ramos HE Arch Endocrinol Metab; 2019; 63(2):97-106. PubMed ID: 30916170 [TBL] [Abstract][Full Text] [Related]
20. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]